DLL4 and neoplasm: Although blocking a pathway that is known to serve as an angiogenic “off switch” seems counterintuitive, agents targeting DLL4 have been shown to reduce tumor growth in vivo by promoting disorganized and non-productive endothelial sprouting and poor tumor perfusion (103).